Abeona Therapeutics Stock Price, News & Analysis (NASDAQ:ABEO)

$16.50 0.40 (2.48 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$16.50
Today's Range$15.90 - $17.63
52-Week Range$4.05 - $22.75
Volume4.61 million shs
Average Volume642,735 shs
Market Capitalization$748.40 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23

About Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics logoAbeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ABEO
CUSIPN/A
Phone214-665-9495

Debt

Debt-to-Equity RatioN/A
Current Ratio22.20%
Quick Ratio22.20%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$890,000.00
Price / Sales867.27
Cash FlowN/A
Price / CashN/A
Book Value$2.48 per share
Price / Book6.65

Profitability

Trailing EPS($0.66)
Net Income$-21,870,000.00
Net Margins-2,946.58%
Return on Equity-27.69%
Return on Assets-25.32%

Miscellaneous

Employees19
Outstanding Shares46,780,000

Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) issued its earnings results on Wednesday, November, 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.06. The biopharmaceutical company had revenue of $0.22 million for the quarter, compared to analysts' expectations of $0.22 million. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. View Abeona Therapeutics' Earnings History.

When will Abeona Therapeutics make its next earnings announcement?

Abeona Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March, 30th 2018. View Earnings Estimates for Abeona Therapeutics.

Where is Abeona Therapeutics' stock going? Where will Abeona Therapeutics' stock price be in 2017?

9 Wall Street analysts have issued twelve-month price objectives for Abeona Therapeutics' stock. Their forecasts range from $15.00 to $35.00. On average, they anticipate Abeona Therapeutics' share price to reach $27.00 in the next twelve months. View Analyst Ratings for Abeona Therapeutics.

What are Wall Street analysts saying about Abeona Therapeutics stock?

Here are some recent quotes from research analysts about Abeona Therapeutics stock:

  • 1. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (11/23/2017)
  • 2. Maxim Group analysts commented, "Abeona reported 3Q17 with a net loss of $5.3M and ended the period with $56.5M in cash. The company also completed an equity financing in October raising $92M in cash. As of 10/31, Abeona reported $143M in cash on the balance sheet, sufficient runway for the next several years." (11/20/2017)
  • 3. Cantor Fitzgerald analysts commented, "At the ASGCT meeting in Washington D.C., Abeona announced initial 30-day data in two patients treated with a high dose of ABO-102." (5/12/2017)
  • 4. FBR & Co analysts commented, "On March 31, Abeona Therapeutics reported results for a year in which all clinical programs achieved important regulatory and clinical milestones. Most notably, 2016 culminated in the initiation of dosing in the high-dose cohort of Abeona’s Phase I/II trial with ABO-102 in children with Sanfilippo Syndrome Type A (MPS IIIA). We think this milestone is significant as it highlights ABO-102’s continued safety, its promising biopotency, as well as its designation for FDA Fast Track status for a rare pediatric disease, as well as for an orphan disease. It also supports our view that Abeona’s ability to rapidly advance therapies with high-value potential and short pathways to regulatory approval remains under-appreciated. We look next for a clinical update on the EB-101 Phase I study later this month, an update on the Phase I/II study with ABO-101 in MPS IIIB, as well as Abeona’s three other ongoing rare disease programs in the next three to six months to be positive catalysts for ABEO stock." (4/5/2017)

Who are some of Abeona Therapeutics' key competitors?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the folowing people:

  • Steven H. Rouhandeh, Executive Chairman of the Board (Age 61)
  • Timothy J. Miller Ph.D., President, Chief Executive Officer, Director (Age 45)
  • Jeffrey B. Davis, Chief Operating Officer (Age 54)
  • David P. Nowotnik Ph.D., Senior Vice President - Research and Development (Age 64)
  • Harrison G. Wehner III, Senior Vice President - Plasma
  • Stephen B. Thompson, Chief Accounting Officer, Vice President - Finance, Treasurer, Secretary (Age 63)
  • Michelle Berg, Vice President - Communications & Operations
  • Andre'a Lucca, Vice President - Communications & Operations
  • Phil Maples Ph.D., Vice President - Therapeutics Development and Quality Management
  • Kaye Spratt Ph.D., Vice President - Regulatory & Quality Assurance

Who owns Abeona Therapeutics stock?

Abeona Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Highbridge Capital Management LLC (1.09%), Royce & Associates LP (0.49%), Point72 Asset Management L.P. (0.45%), EAM Investors LLC (0.32%), Perceptive Advisors LLC (0.25%) and Allianz Asset Management GmbH (0.23%). View Institutional Ownership Trends for Abeona Therapeutics.

Who sold Abeona Therapeutics stock? Who is selling Abeona Therapeutics stock?

Abeona Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, Perceptive Advisors LLC, Royce & Associates LP, Essex Investment Management Co. LLC, Allianz Asset Management GmbH and California State Teachers Retirement System. View Insider Buying and Selling for Abeona Therapeutics.

Who bought Abeona Therapeutics stock? Who is buying Abeona Therapeutics stock?

Abeona Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., EAM Investors LLC, Wells Fargo & Company MN and Family Management Corp. View Insider Buying and Selling for Abeona Therapeutics.

How do I buy Abeona Therapeutics stock?

Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abeona Therapeutics' stock price today?

One share of Abeona Therapeutics stock can currently be purchased for approximately $16.50.

How big of a company is Abeona Therapeutics?

Abeona Therapeutics has a market capitalization of $748.40 million and generates $890,000.00 in revenue each year. The biopharmaceutical company earns $-21,870,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Abeona Therapeutics employs 19 workers across the globe.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495 or via email at [email protected]


MarketBeat Community Rating for Abeona Therapeutics (ABEO)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  254 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  362
MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abeona Therapeutics (NASDAQ:ABEO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.00$24.33$19.71$16.83
Price Target Upside: 67.18% upside69.87% upside40.07% upside220.63% upside

Abeona Therapeutics (NASDAQ:ABEO) Consensus Price Target History

Price Target History for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ:ABEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/22/2017HC WainwrightReiterated RatingBuy$30.00N/AView Rating Details
11/22/2017Jefferies GroupReiterated RatingBuy$28.00N/AView Rating Details
11/20/2017Maxim GroupSet Price TargetBuy$35.00N/AView Rating Details
11/8/2017SunTrust BanksInitiated CoverageBuy$26.00N/AView Rating Details
10/11/2017Cantor FitzgeraldBoost Price TargetOverweight$21.00 -> $34.00N/AView Rating Details
10/10/2017CitigroupInitiated CoverageBuy$32.00N/AView Rating Details
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform -> Outperform$23.00HighView Rating Details
5/26/2017FBR & CoReiterated RatingBuyN/AView Rating Details
2/7/2017Rodman & RenshawReiterated RatingBuy$17.00 -> $20.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Abeona Therapeutics (NASDAQ:ABEO) Earnings History and Estimates Chart

Earnings by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ ABEO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/30/2018        
11/15/2017Q3 2017($0.19)($0.13)$0.22 million$0.22 millionViewN/AView Earnings Details
8/15/2017Q2 2017($0.14)($0.21)$0.21 million$0.22 millionViewN/AView Earnings Details
5/18/2017Q1 2017($0.15)($0.13)$0.28 million$0.19 millionViewN/AView Earnings Details
3/31/201712/31/2016($0.14)($0.19)$0.19 million$0.26 millionViewN/AView Earnings Details
11/14/2016Q316($0.19)($0.08)$0.23 million$0.18 millionViewN/AView Earnings Details
8/16/2016Q2($0.14)($0.20)$0.27 million$0.21 millionViewN/AView Earnings Details
3/30/2016Q1($0.13)($0.17)$0.22 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Abeona Therapeutics (NASDAQ:ABEO) Earnings Estimates

2017 EPS Consensus Estimate: ($0.52)
2018 EPS Consensus Estimate: ($0.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20172($0.12)($0.12)($0.12)
Q3 20173($0.23)($0.11)($0.16)
Q4 20173($0.13)($0.12)($0.12)
Q1 20181($0.15)($0.15)($0.15)
Q2 20181($0.15)($0.15)($0.15)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Abeona Therapeutics (NASDAQ:ABEO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Abeona Therapeutics (NASDAQ ABEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 41.95%
Insider Trades by Quarter for Abeona Therapeutics (NASDAQ:ABEO)
Institutional Ownership by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ ABEO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2016Todd WiderDirectorBuy5,000$5.48$27,400.00View SEC Filing  
7/31/2015Mark J AhnDirectorBuy18,182$5.50$100,001.00View SEC Filing  
1/26/2015Mark J AhnDirectorBuy25,000$4.00$100,000.00View SEC Filing  
12/24/2014Steven H RouhandehDirectorBuy250,000$4.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Abeona Therapeutics (NASDAQ ABEO) News Headlines

Source:
DateHeadline
Financial Contrast: Durata Therapeutics (DRTX) versus Abeona Therapeutics (ABEO)Financial Contrast: Durata Therapeutics (DRTX) versus Abeona Therapeutics (ABEO)
www.americanbankingnews.com - December 13 at 8:48 AM
Biotech Stocks Research Reports Released on PhaseRx, Abeona Therapeutics, Imprimis Pharma, and Jaguar Health - PR Newswire (press release)Biotech Stocks' Research Reports Released on PhaseRx, Abeona Therapeutics, Imprimis Pharma, and Jaguar Health - PR Newswire (press release)
www.prnewswire.com - December 9 at 3:43 PM
Adverum: Preparing For Liftoff. The Next Abeona - Seeking AlphaAdverum: Preparing For Liftoff. The Next Abeona - Seeking Alpha
seekingalpha.com - December 7 at 3:48 PM
Relieving Suffering From Genetic Disease - Abeona Therapeutics - Seeking AlphaRelieving Suffering From Genetic Disease - Abeona Therapeutics - Seeking Alpha
seekingalpha.com - December 6 at 11:19 AM
Zacks: Analysts Anticipate Abeona Therapeutics Inc (ABEO) Will Post Quarterly Sales of $240,000.00Zacks: Analysts Anticipate Abeona Therapeutics Inc (ABEO) Will Post Quarterly Sales of $240,000.00
www.americanbankingnews.com - December 5 at 8:37 AM
Critical Review: Abeona Therapeutics (ABEO) & ChromaDex (CDXC)Critical Review: Abeona Therapeutics (ABEO) & ChromaDex (CDXC)
www.americanbankingnews.com - December 2 at 9:38 AM
Abeona Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ABEO-US : November 27, 2017Abeona Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ABEO-US : November 27, 2017
finance.yahoo.com - November 27 at 3:23 PM
Abeona Therapeutics Inc. (ABEO) Receives Average Rating of "Buy" from AnalystsAbeona Therapeutics Inc. (ABEO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 27 at 12:12 PM
Abeona Therapeutics Inc. (ABEO) Stock Rating Lowered by Zacks Investment ResearchAbeona Therapeutics Inc. (ABEO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - November 23 at 8:42 PM
Abeona Therapeutics (ABEO) Buy Rating Reiterated at Jefferies Group LLCAbeona Therapeutics' (ABEO) Buy Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - November 23 at 7:20 PM
FY2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By Jefferies Group (ABEO)FY2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By Jefferies Group (ABEO)
www.americanbankingnews.com - November 23 at 8:52 AM
FY2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By SunTrust Banks (ABEO)FY2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By SunTrust Banks (ABEO)
www.americanbankingnews.com - November 23 at 8:52 AM
Abeona Therapeutics Inc. (ABEO) Stock Rating Upgraded by Zacks Investment ResearchAbeona Therapeutics Inc. (ABEO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 22 at 10:48 PM
Abeona Therapeutics Inc. (ABEO) Given Buy Rating at HC WainwrightAbeona Therapeutics Inc. (ABEO) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - November 22 at 4:26 PM
Featured Company News - Celldex Starts Phase-2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell CarcinomaFeatured Company News - Celldex Starts Phase-2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
finance.yahoo.com - November 22 at 3:56 PM
FY2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By Cantor Fitzgerald (ABEO)FY2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By Cantor Fitzgerald (ABEO)
www.americanbankingnews.com - November 22 at 6:46 AM
Edited Transcript of ABEO earnings conference call or presentation 20-Nov-17 3:00pm GMTEdited Transcript of ABEO earnings conference call or presentation 20-Nov-17 3:00pm GMT
finance.yahoo.com - November 21 at 3:03 AM
Abeona Therapeutics (ABEO) CEO Tim Miller on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAbeona Therapeutics' (ABEO) CEO Tim Miller on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 20 at 10:00 PM
Maxim Group Reiterates "$35.00" Price Target for Abeona Therapeutics Inc. (ABEO)Maxim Group Reiterates "$35.00" Price Target for Abeona Therapeutics Inc. (ABEO)
www.americanbankingnews.com - November 20 at 3:32 PM
Abeona Therapeutics (ABEO) Presents At Jefferies 2017 London Healthcare Conference - SlideshowAbeona Therapeutics (ABEO) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 18 at 12:57 AM
Abeona Therapeutics, Inc. – Value Analysis (NASDAQ:ABEO) : November 17, 2017Abeona Therapeutics, Inc. – Value Analysis (NASDAQ:ABEO) : November 17, 2017
finance.yahoo.com - November 17 at 3:17 PM
$230,000.00 in Sales Expected for Abeona Therapeutics Inc. (ABEO) This Quarter$230,000.00 in Sales Expected for Abeona Therapeutics Inc. (ABEO) This Quarter
www.americanbankingnews.com - November 17 at 12:12 PM
Abeona Therapeutics reports 3Q loss - Yahoo FinanceAbeona Therapeutics reports 3Q loss - Yahoo Finance
finance.yahoo.com - November 16 at 10:33 AM
Abeona Reports Third Quarter 2017 Financial Results and Recent Business HighlightsAbeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
finance.yahoo.com - November 16 at 10:33 AM
Abeona Therapeutics reports 3Q lossAbeona Therapeutics reports 3Q loss
finance.yahoo.com - November 16 at 10:33 AM
Abeona Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ABEO-US : November 16, 2017Abeona Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ABEO-US : November 16, 2017
finance.yahoo.com - November 16 at 10:33 AM
Abeona Therapeutics Inc. (ABEO) Issues  Earnings ResultsAbeona Therapeutics Inc. (ABEO) Issues Earnings Results
www.americanbankingnews.com - November 15 at 3:42 PM
Abeona Management to Present at Multiple Conferences in NovemberAbeona Management to Present at Multiple Conferences in November
finance.yahoo.com - November 14 at 2:53 AM
Abeona Therapeutics (ABEO) Announces Enrollment of First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in ... - StreetInsider.comAbeona Therapeutics (ABEO) Announces Enrollment of First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in ... - StreetInsider.com
www.streetinsider.com - November 10 at 8:32 AM
Q3 2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By SunTrust Banks (ABEO)Q3 2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By SunTrust Banks (ABEO)
www.americanbankingnews.com - November 10 at 7:47 AM
Q3 2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By SunTrust Banks (ABEO)Q3 2017 Earnings Estimate for Abeona Therapeutics Inc. Issued By SunTrust Banks (ABEO)
www.americanbankingnews.com - November 10 at 7:47 AM
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIAAbeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
finance.yahoo.com - November 9 at 4:17 PM
Abeona Therapeutics Inc. (ABEO) Receives New Coverage from Analysts at SunTrust Banks, Inc.Abeona Therapeutics Inc. (ABEO) Receives New Coverage from Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - November 8 at 9:50 AM
Noteworthy Tuesday Option Activity: SFLY, ABEO, SUPNNoteworthy Tuesday Option Activity: SFLY, ABEO, SUPN
www.thestreet.com - November 7 at 4:50 PM
Abeona Therapeutics Inc. (ABEO) Receives Average Recommendation of "Buy" from AnalystsAbeona Therapeutics Inc. (ABEO) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 2 at 3:28 PM
-$0.16 Earnings Per Share Expected for Abeona Therapeutics Inc. (ABEO) This Quarter-$0.16 Earnings Per Share Expected for Abeona Therapeutics Inc. (ABEO) This Quarter
www.americanbankingnews.com - October 25 at 4:10 PM
Market Still Lacks Ability to Find VolatilityMarket Still Lacks Ability to Find Volatility
finance.yahoo.com - October 20 at 3:28 PM
Abeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesAbeona Announces Closing of $92 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - October 19 at 3:18 PM
Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher - NasdaqAbeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher - Nasdaq
www.nasdaq.com - October 18 at 3:28 PM
Abeona Shares Higher After Pricing Stock Offering -- Biotech MoversAbeona Shares Higher After Pricing Stock Offering -- Biotech Movers
finance.yahoo.com - October 17 at 3:30 PM
Abeona Therapeutics Announces Public Offering of Common Stock - GlobeNewswire (press release)Abeona Therapeutics Announces Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - October 17 at 1:22 AM
Abeona Therapeutics Announces Pricing of Public Offering of Common StockAbeona Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 17 at 1:22 AM
BRIEF-Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programsBRIEF-Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programs
www.reuters.com - October 16 at 8:19 PM
Abeona Therapeutics Announces Public Offering of Common StockAbeona Therapeutics Announces Public Offering of Common Stock
finance.yahoo.com - October 16 at 8:19 PM
Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene TherapiesAbeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies
finance.yahoo.com - October 16 at 3:19 PM
Abeona Therapeutics (ABEO) versus The Competition Head to Head ReviewAbeona Therapeutics (ABEO) versus The Competition Head to Head Review
www.americanbankingnews.com - October 12 at 6:12 AM
Abeona Therapeutics (ABEO) Announces Enrollment of First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIAAbeona Therapeutics (ABEO) Announces Enrollment of First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
www.streetinsider.com - October 12 at 12:15 AM
Cantor Fitzgerald Increases Abeona Therapeutics Inc. (ABEO) Price Target to $34.00Cantor Fitzgerald Increases Abeona Therapeutics Inc. (ABEO) Price Target to $34.00
www.americanbankingnews.com - October 11 at 3:58 PM
Are Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock? - NasdaqAre Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock? - Nasdaq
www.nasdaq.com - October 11 at 3:26 PM
Opinion: Harry Boxers four stocks to watch today - MarketWatchOpinion: Harry Boxer's four stocks to watch today - MarketWatch
www.marketwatch.com - October 11 at 3:26 PM

SEC Filings

Abeona Therapeutics (NASDAQ:ABEO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Abeona Therapeutics (NASDAQ:ABEO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Abeona Therapeutics (NASDAQ ABEO) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.